Poor
Not Aligned
Patient Risk:
Moderate
Summary
The provided FDA label excerpts only support boxed-warning suicidality and pediatric weight/growth monitoring. Most other claims (brand/generic, indications, dosing, side effects, mechanism, patent/generics pricing, enantiomer/potency, and specific drug interactions) are not supported or not assessable from the supplied labeling text, leading to many unsupported statements.
Category Scores
Accurate Statements
Antidepressants (including escitalopram/SSRIs) increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients, and patients should be closely monitored (especially early in treatment and around dose changes).
Boxed Warning (as provided), Section 5.1, and Section 17 all support the increased risk and monitoring timing/dose-change emphasis.
Unsupported Statements
The brand name for escitalopram 10 mg is Lexapro.
Not supported by the supplied FDA label excerpts (only suicidality/pediatric monitoring excerpts provided).
Lexapro is prescribed to treat major depressive disorder in adults and adolescents.
Not supported by the supplied FDA label excerpts.
Lexapro is prescribed to treat generalized anxiety disorder in adults.
Not supported by the supplied FDA label excerpts.
Lexapro is an antidepressant in the class of selective serotonin reuptake inhibitors (SSRIs).
Not supported by the supplied FDA label excerpts provided.
Lexapro works by increasing the amount of serotonin in the brain.
Not supported by the supplied FDA label excerpts.
The patents for Lexapro have expired, allowing the availability of generic versions.
Not supported by the supplied FDA label excerpts (regulatory/patent status not contained in provided text).
Common side effects of Lexapro can include nausea.
Not supported by the supplied FDA label excerpts.
Common side effects of Lexapro can include insomnia.
Not supported by the supplied FDA label excerpts.
Common side effects of Lexapro can include ejaculation disorder.
Not supported by the supplied FDA label excerpts.
Common side effects of Lexapro can include fatigue.
Not supported by the supplied FDA label excerpts.
Common side effects of Lexapro can include increased sweating.
Not supported by the supplied FDA label excerpts.
Generic versions of escitalopram are available.
Not supported by the supplied FDA label excerpts.
Generic versions of escitalopram are typically less expensive than the brand-name drug Lexapro.
Not supported by the supplied FDA label excerpts.
Escitalopram is the S-enantiomer of citalopram.
Not supported by the supplied FDA label excerpts.
Escitalopram and racemic citalopram are both SSRIs used for similar conditions.
Not supported by the supplied FDA label excerpts.
Escitalopram is generally considered to be more potent than racemic citalopram.
Not supported by the supplied FDA label excerpts.
Escitalopram may have a more favorable side effect profile than racemic citalopram.
Not supported by the supplied FDA label excerpts.
Escitalopram can interact with other antidepressants.
Not supported by the supplied FDA label excerpts.
Escitalopram can interact with blood thinners.
Not supported by the supplied FDA label excerpts.
Escitalopram can interact with certain pain medications.
Not supported by the supplied FDA label excerpts.
Contradictions
Important Omissions
Pediatric-specific monitoring/weight and growth monitoring due to SSRIs (decreased appetite and weight loss) as stated in Section 8.4.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The only label-supported safety content provided relates to suicidality monitoring. Other safety-relevant claims (adverse reactions and drug interactions) were not supported by the provided excerpts, so alignment to the supplied label on those points cannot be confirmed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the supplied FDA label excerpts; only the boxed warning/monitoring for suicidal thoughts in pediatric and young adult patients is supported.
Suggested Improvement
Restrict statements to label-supported content from the provided excerpts (Boxed Warning/Section 5.1/Section 17 and Section 8.4 weight/growth monitoring). Remove or qualify unverified claims about indications, side effects, generics/pricing, mechanism, enantiomer/potency, and drug interactions unless those sections are provided.